Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Authors not listed
Eli Lilly and Company · 2014
Abstract
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2014). Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study). <em>Eli Lilly and Company</em>. https://clinicaltrials.gov/study/NCT02008357
Vancouver
Anonymous. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study). Eli Lilly and Company. 2014.
BibTeX
@misc{anon2014AntiAm,
title = {Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)},
author = {Anonymous},
journal = {Eli Lilly and Company},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Eli Lilly and Company 2016
Open access · US-GOV
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
University of California, Los Angeles 2000
Open access · US-GOV
Anti-Inflammation in AD: PET Imaging Supplement
Seoul National University Hospital 2014
Open access · US-GOV
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease
US Department of Veterans Affairs 1999
Open access · US-GOV
Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach
JHSPH Center for Clinical Trials 2009
Open access · US-GOV